Oruka Therapeutics Statistics
Total Valuation
ORKA has a market cap or net worth of $7.15 billion. The enterprise value is $5.94 billion.
| Market Cap | 7.15B |
| Enterprise Value | 5.94B |
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ORKA has 67.82 million shares outstanding. The number of shares has increased by 42.31% in one year.
| Current Share Class | 67.82M |
| Shares Outstanding | 67.82M |
| Shares Change (YoY) | +42.31% |
| Shares Change (QoQ) | +13.87% |
| Owned by Insiders (%) | 2.16% |
| Owned by Institutions (%) | 99.95% |
| Float | 58.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.93 |
| P/TBV Ratio | 5.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.62, with a Debt / Equity ratio of 0.00.
| Current Ratio | 29.62 |
| Quick Ratio | 28.96 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.12% and return on invested capital (ROIC) is -13.55%.
| Return on Equity (ROE) | -18.12% |
| Return on Assets (ROA) | -13.15% |
| Return on Invested Capital (ROIC) | -13.55% |
| Return on Capital Employed (ROCE) | -15.27% |
| Weighted Average Cost of Capital (WACC) | 3.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.92M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +272.26% in the last 52 weeks. The beta is -0.17, so ORKA's price volatility has been lower than the market average.
| Beta (5Y) | -0.17 |
| 52-Week Price Change | +272.26% |
| 50-Day Moving Average | 89.68 |
| 200-Day Moving Average | 72.65 |
| Relative Strength Index (RSI) | 64.42 |
| Average Volume (20 Days) | 998,113 |
Short Selling Information
The latest short interest is 6.46 million, so 9.53% of the outstanding shares have been sold short.
| Short Interest | 6.46M |
| Short Previous Month | 6.11M |
| Short % of Shares Out | 9.53% |
| Short % of Float | 11.05% |
| Short Ratio (days to cover) | 6.99 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -183.11M |
| Pretax Income | -152.57M |
| Net Income | -130.37M |
| EBITDA | -182.95M |
| EBIT | -183.11M |
| Earnings Per Share (EPS) | -$2.13 |
Balance Sheet
The company has $1.21 billion in cash and investments and $2.93 million in debt, with a net cash position of $1.20 billion or $17.75 per share.
| Cash & Investments | 1.21B |
| Total Debt | 2.93M |
| Net Cash | 1.20B |
| Net Cash Per Share | $17.75 |
| Equity (Book Value) | 1.20B |
| Book Value Per Share | 17.78 |
| Working Capital | 909.71M |
Cash Flow
In the last 12 months, operating cash flow was -$123.64 million and capital expenditures -$219,000, giving a free cash flow of -$123.86 million.
| Operating Cash Flow | -123.64M |
| Capital Expenditures | -219,000 |
| Depreciation & Amortization | 163,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -123.86M |
| FCF Per Share | -$1.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORKA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -42.31% |
| Shareholder Yield | -42.31% |
| Earnings Yield | -2.03% |
| FCF Yield | -1.73% |
Analyst Forecast
The average price target for ORKA is $156.17, which is 48.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $156.17 |
| Price Target Difference | 48.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 3, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Sep 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |